Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung Adenocarcinoma

NCT00903292 is registered in ClinicalTrials.gov with National Cheng-Kung University Hospital as lead sponsor.

NCT NCT00903292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00903292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Tailored Second Line Treatment by EGFR Mutation in Patients With Advanced Lung Adenocarcinoma
Lead sponsor
National Cheng-Kung University Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
March 31, 2009
Completion date
December 31, 2010
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer